Main Article Content
Background: Gynecological oncology patients have been suffering from cancer and a set of symptom cluster from treatment. To pass the suffering from the first cycle of chemotherapy is meant that patients can pass all the left five cycles of them. Purposes of this study were to examine (1) symptom occurrence and severity after chemotherapy day 1 to 14 and (2) the change of symptom cluster occurrences in Thai gynecologic oncology patients receiving first cycle of Carboplatin and Paclitaxel at day 1. 3,7, and 14.
Methods: This is descriptive study One hundred and ten women were recruited from gynecologic oncology department in a hospital affiliated university. The National Cancer Institute Symptom Severity Diary and the Demographic, Disease, and Treatment Questionnaires were used to collected data. The National Cancer Institute Symptom Severity Diary was recorded from the 1st day to 14th day after first cycle of chemotherapy. Factor analysis was used for analyzing data.
Results: Results reported top five most symptom occurrences were fatigue, numbness, anorexia, pain, and constipation. Top 5 most symptom severity were pain, numbness, fatigue, anorexia, and alopecia. These symptom were changed from day 1-14 after receiving first cycle of Carboplatin and Paclitaxel. There were 2 clusters of symptom occurrence at day 1 after receiving chemotherapy were neuropathy side effects and gastro – intestinal effects. At day 3, there were gastro – intestinal effects and sleep pattern change. At day 7, there were gastro – intestinal effects; neuropathy side effects; and sleep pattern change. Lastly, at day14, there were gastro – intestinal effects and neuropathy side effects.
Conclusions: Findings provided an evidenced data for side effects’ management appropriate with context in gynecological oncology patients receiving the first cycle of Carboplatin and Paclitaxel.
Sumdaengrit B. The symptom experience and self care in Thai women with cervical cancer receiving treatment [dissertation]. Bangkok; Mahidol University; 2008.
Sumdaengrit B, Huncharurnkul S, Dodd MJ, Wilailuk S, Vorapongsathorn T, Pongthavornkamol K. Factors predicting the change of symptom distress among Thai women with cervical cancer. Rama Med J. 2011;34:45-57.
Dodd MJ, Janson S, Facione N, et al. Advancing the science of symptom management. J Adv Nurs. 2001;33:668-76.
Barsevick AM, Whitmer K, Nail LM, Beck SL, Dudley WN. Symptom cluster research: conceptual, design, measurement, and analysis issues. J Pain Symptom Manage. 2006;31(1):85-95.
Xiao C. The state of science in the study of cancer symptom clusters. Eur J Oncol Nurs. 2010;14:417-34.
Chen ML, Tseng HH. Identification and verification of symptom clusters in cancer patients. J Support Oncol. 2005;3(6 Suppl 4):28-9.
Thamnipa P, Konsue P, Therasakvichya S. Perception of symptoms and symptom management of side effects in ovarian cancer patients receiving chemotherapy. J Nurs Sci. 2014;32:28-38.
The Eastern Cooperative Oncology Group (ECOG) Performance Status 2016 [cite 2016 February 26] Available from: www.npcrc.org/files/news/ECOG_performance_status.pdf.
Shirakul K, Trakoolpiankit P, Tantasaensook K. Pharmacology of cancer chemotherapy. In: Leenasmith W, Srisupan S, editors. Gynecologic Oncology. 2nd ed. Bangkok: Holistic Jones and Bartlett publishers; 2005:313-40.
Phianmongkhol Y, Suwan N. Symptom management in patients with cancer of the female reproductive system receiving chemotherapy. Asian Pac J Cancer Prev. 2008;9:741-5.
Kietpeerakool C, Suprasert P, Srisomboon, J. Adverse effects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer. J Med Assoc Thai. 2005;88:301-6.
Karabulu N, Erci B, Ozer N, Ozdemir S. Symptom clusters and experiences of patients with cancer. J Adv Nurs. 2009;1011-21.
Chan CW, Richardson A, Richardson J. An investigation of a symptom cluster in Chinese patients with lung cancer receiving radiotherapy. Contemp Nurse. 2013;45164-73.
Skerman HM, Yates PM, Battistutta D. Cancer-related symptom clusters for symptom management in outpatients after commencing adjuvant chemotherapy, at 6 months, and 12 months. Support Care Cancer. 2012;20:95-105.